Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years

Completed · Phase 3

Conditions studied: Cystic Fibrosis

In brief

This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of elexacaftor (ELX)/tezacaftor (TEZ)/ivacaftor (IVA) triple combination therapy in CF subjects 2 through 5 years of age.

Key facts

Study ID
NCT04537793
Run by
Vertex Pharmaceuticals Incorporated
People needed
83
Starts
2020-11-19
Expected to finish
2022-06-03
Last updated by the study team
2023-06-28

Who can join

Age: 2 and older, up to 5. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.